

TO: Providers of Pharmaceutical Services,  
Chief Executive Officers - Hospitals,  
Physicians, Dentists, Podiatrists and Independent Clinics

SUBJECT: Drug Efficacy Study Implementation (DESI)  
Update of Drug Products and Known Related Drug Products that Lack Substantia

EFFECTIVE: May 11, 1992

BACKGROUND: The Division of Medical Assistance and Health Services does not reimburse for drugs that the federal Food and Drug Administration (FDA) has proposed to withdraw from the market. In addition, Section 2103 of the Omnibus Budget Reconciliation Act (Codified as 1903 (i) (5) of the Social Security Act) requires this action for all identical, related or similar drugs.

ACTION: The Division of Medical Assistance and Health Services will not reimburse for drugs listed under the federal Drug Efficacy Study Implementation (DESI).

This action applies to the New Jersey Medicaid program, the Pharmaceutical Assistance to the Aged and Disabled (PAAD) program, the General Assistance program, the Garden State Health Plan, and the Cystic Fibrosis Drug program.

Attached for your convenience is an updated list of generic/brand named DESI drugs provided in sequential National Drug Code (NDC) order that are considered less than effective under the federal DESI program. The DESI list distributed to providers on October 8, 1990 (BC-475) may be discarded.

If you have any questions regarding this Newsletter, please contact the New Jersey Medicaid program, Chief Pharmacy Consultant, at 1-609-588-2724.